Sonelokimab Demonstrates Psoriatic Arthritis Improvements Over Placebo Victoria Johnson

Published Date: 21 Nov 2025

Sonelokimab meets ACR50 primary endpoint in a phase 2 trial.

Read Full News

Latest News

Lupus Can Cost Young Women More Years Than Diabetes, HIV

Lupus contributes substantially to premature mortality in young women, with over 304,000 years of potential life lost in women aged 15-44 years from 2000 to 2015.

Pulmonary Fibrosis Video Diaries: Patient Experiences and Timely Diagnosis of IPF

Pulmonary Fibrosis Video Diaries: Patient Experiences and Timely Diagnosis of IPF

From Evidence to Action: Practical Strategies for FcRn Therapy in gMG

From Evidence to Action: Practical Strategies for FcRn Therapy in gMG

Next-Gen Therapies for gMG: The Science and Support for FcRn Antagonists

Next-Gen Therapies for gMG: The Science and Support for FcRn Antagonists

Strategies for Personalized CIDP Care: Patient Selection, Treatment Transition, and FcRn Therapy

Strategies for Personalized CIDP Care: Patient Selection, Treatment Transition, and FcRn Therapy

Transforming CIDP Management: Early Diagnosis, Pathophysiology, and the Emerging Role of FcRn Antagonists

Transforming CIDP Management: Early Diagnosis, Pathophysiology, and the Emerging Role of FcRn Antagonists

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Latest News

Lupus contributes substantially to premature mortality in young women, with over 304,000 years of potential life lost in women aged 15-44 years from 2000 to 2015.

Pulmonary Fibrosis Video Diaries: Patient Experiences and Timely Diagnosis of IPF

From Evidence to Action: Practical Strategies for FcRn Therapy in gMG

Next-Gen Therapies for gMG: The Science and Support for FcRn Antagonists

Strategies for Personalized CIDP Care: Patient Selection, Treatment Transition, and FcRn Therapy

Transforming CIDP Management: Early Diagnosis, Pathophysiology, and the Emerging Role of FcRn Antagonists

News All Time

Osteoarthritis: Promising Drug Therapy Flops

No help from diacerein in randomized trial

Another B-Cell Drug for Lupus Hits the Mark

Phase III results put obinutuzumab in line for approval

Europe Does Better Than U.S. in Treating Spondyloarthritis, Survey Data Suggest

American patients report more symptoms and mostly don't agree with doctors on how they've fared

Medicare Coverage Appears Spotty for Newer Rheumatoid Arthritis Meds

Advantage plans do a better job than standalone Part D policies, albeit with important gaps

ICE Chief Hospitalized; Metastatic Colon Cancer at Age 26; TENS for Fibromyalgia

Health news and commentary gathered by MedPage Today staff

Dyspnea in Woman With RA Reveals a Diaphragmatic Lipoma

MRI can help differentiate these benign soft-tissue masses from more aggressive liposarcomas

What Caused This Patient's Recurring Eye and Ear Inflammation?

Prompt diagnosis of this rare progressive autoimmune disease may help preserve hearing, eyesight

What Caused Left-Sided Hearing Loss in This 65-Year-Old Man?

Numerous diagnostic procedures revealed tophaceous gout affecting the middle ear

EULAR: Docs Should Push Hard on Physical Activity for Arthritis Patients

We have met the enemy and it's the sofa, updated guideline indicates

Rheumatic Disease Drugs Help COVID Virus Stick Around Longer, Study Suggests

Lengthy viral antigen persistence far more common, regardless of prior vaccination

Drug Targeting TLRs in Cutaneous Lupus Looks Good in Mid-Stage Studies

— Dose-response signal appears in phase II trial, and all doses are better than placebo

Upadacitinib After TNF Inhibitor Failure Improves RA Control

In patients with active RA, switching to upadacitinib after failure of a single TNF inhibitor is more effective in reducing disease activity at 12 weeks than using a second TNF inhibitor adalimumab.

Early Anti-TNF to Prevent Difficult-to-Treat RA Gains Steam

The availability of TNF inhibitor biosimilars and the cost of treating ‘difficult-to-treat’ RA are making first-line TNF inhibition in early RA more attractive in the UK.

FDA Grants Breakthrough Therapy Designation to Ianalumab, First Potential Sjögren’s Targeted Therapy Victoria Johnson

Novartis plans to submit regulatory applications for ianalumab in early 2026.

FDA Updates Label for Reduced Osteoarthritis Risk With BEAR Implant Over ACL Reconstruction Victoria Johnson

FDA approves a label update for the BEAR implant, which was previously approved in 2020.

FDA Grants Priority Review to Efgartigimod, First Potential Therapy for Seronegative Myasthenia Gravis Victoria Johnson

argenx's efgartigimod-alfa therapy was approved for seropositive generalized myasthenia gravis in 2021.

Recommended News For You

CAR-T cell therapy for cancer causes 'brain fog,' study shows

Paging Dr. AI; Myth Busting in Cancer; Oncologists Shine in Malpractice Survey

Study suggests around 40% of postmenopausal hormone positive breast cancers are linked to excess body fat

AI tool automates liver tumor detection and monitoring

New clinical recommendation for local treatment of oligometastatic lung cancer.

Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.

Study Supports Lactated Ringer Solution for Fluid Resuscitation in SCD

Recommended Articles For You

Beyond the Standard: Personalized Cancer Vaccines and the Dawn of a New Era in Pediatric Oncology 

Unlocking the Secrets of Hemoglobin: Exploring the Wonders of Life-Sustaining Iron Compounds 

Impact of Hormone Therapy Cessation on Tumor Growth: Case Study of Ki-67 Reduction 

Interpreting Iron Studies: What Your Blood Results Really Mean  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Does pollution cause cancer?

2.

AI is equally capable of reading breast cancer scans as human radiologists.

3.

EVP Beats Cisplatin for Resectable MIBC

4.

New research points out a promising strategy for treating metastatic medulloblastoma

5.

Academics + Pharma = Big Bucks; New CAR-T Warnings; Patients Seek Cancer Tests.

1.

A Closer Look at Breast Cancer: Examining the Ultrasound Images

2.

Unlocking the Secrets of Oral Cancer Staging: A New Approach to Early Detection

3.

Impact of Hormone Therapy Cessation on Tumor Growth: Case Study of Ki-67 Reduction

4.

Unraveling the Mysteries of Lymphoma: A Journey into the Unknown

5.

Refining AML Survival: Prognostic Factors, Therapies, and Stem Cell Strategies Reviewed

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Navigating the Complexities of Ph Negative ALL - Part III

2.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII

3.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)

4.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III

5.

Virtual Case Study on Pedal Edema and Triple Vessel Disease - An Initiative by Hidoc Dr.

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot